Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech
In developing any antibody-drug conjugate, the linker — the hyphen between the antigen-binding antibody and the cancer-killing drug — is of utmost importance. Link too much payload to the antibody too loosely, and you risk triggering off-site toxicity while the ADC is circulating through blood; link too little, and it falls short of the goal to kill off cancer cells from within. And while a host of drugmakers have followed Seattle Genetics’ lead into new linker technology, in some cases deploying engineering the antibodies, there’s still much to be learned about controlling the resulting ADCs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters